Traders Purchase Large Volume of Call Options on ADMA Biologics (NASDAQ:ADMA)

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report) saw unusually large options trading activity on Monday. Stock traders bought 11,474 call options on the company. This represents an increase of approximately 539% compared to the average volume of 1,797 call options.

ADMA Biologics Stock Performance

NASDAQ ADMA traded down $0.14 during trading hours on Monday, hitting $22.48. The company had a trading volume of 4,726,151 shares, compared to its average volume of 4,106,896. The company has a market cap of $5.24 billion, a PE ratio of 80.29 and a beta of 0.64. ADMA Biologics has a 1-year low of $3.60 and a 1-year high of $23.64. The business has a 50 day moving average of $18.12 and a 200-day moving average of $13.95. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 59.29%. The business's revenue was up 78.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.02) earnings per share. As a group, equities research analysts expect that ADMA Biologics will post 0.51 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Cantor Fitzgerald restated an "overweight" rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Raymond James boosted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday. Finally, HC Wainwright lifted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday.

Insiders Place Their Bets

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Lawrence P. Guiheen sold 9,000 shares of the firm's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Young Kwon sold 60,000 shares of the business's stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the transaction, the director now directly owns 241,441 shares of the company's stock, valued at approximately $4,408,712.66. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 466,900 shares of company stock worth $8,224,121. Company insiders own 3.70% of the company's stock.

Institutional Trading of ADMA Biologics

Several large investors have recently modified their holdings of ADMA. Intech Investment Management LLC acquired a new stake in shares of ADMA Biologics in the third quarter worth approximately $1,242,000. Jennison Associates LLC purchased a new stake in ADMA Biologics during the 3rd quarter worth $690,000. New Millennium Group LLC acquired a new position in shares of ADMA Biologics in the third quarter worth about $4,139,000. Aviance Capital Partners LLC acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at approximately $229,000. Finally, First Turn Management LLC acquired a new stake in ADMA Biologics in the third quarter valued at $13,293,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.